Earnings Summary

Iradimed Corp’s revenue jumped 17.42% since last year same period to $17.45Mn in the Q4 2023. On a quarterly growth basis, Iradimed Corp has generated 5.74% jump in its revenue since last 3-months.

Iradimed Corp’s net profit jumped 23.58% since last year same period to $4.54Mn in the Q4 2023. On a quarterly growth basis, Iradimed Corp has generated -10.41% fall in its net profits since last 3-months.

Iradimed Corp’s net profit margin jumped 5.25% since last year same period to 26.01% in the Q4 2023. On a quarterly growth basis, Iradimed Corp has generated -15.27% fall in its net profit margins since last 3-months.

Iradimed Corp’s price-to-earnings ratio after this Q4 2023 earnings stands at 30.96.

Iradimed Corp’s earning per share (EPS) estimates for the current quarter stand at 0.33 - a -17.5% fall from last quarter’s estimates.

Iradimed Corp’s earning per share (EPS) estimates for the current year stand at 0.33.

Iradimed Corp’s earning per share (EPS) jumped 21.88% since last year same period to 0.39 in the Q4 2023. This indicates that the Iradimed Corp has generated 21.88% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Iradimed Corp’s return on assets (ROA) stands at 0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Iradimed Corp’s return on equity (ROE) stands at 0.24.

Iradimed Corp declared 0.48 dividend per share during the earnings announcement for Q4 2023.